Physician profile
Eli Hammer
NPI 1730641556
$1,804.90
in general payments reported to CMS, 2019-2025
20 companies · $425 in 2025
The $425 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.90 · 2022: $255 · 2023: $691 · 2024: $419 · 2025: $425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,536.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,535.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $327.90 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $274.85 | 2023-2025 | |
| Glaxosmithkline, LLC. | $206.53 | 2022-2025 | Shingrix, Arexvy, Bexsero |
| Lilly USA, LLC | $201.69 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $112.19 | 2023-2025 | |
| Paratek Pharmaceuticals, INC. | $93.50 | 2022-2023 | Nuzyra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.41 | 2022-2024 | Jardiance, Synjardy |
| Irhythm Technologies, INC. | $75.06 | 2024 | Zio Monitor, Zio Xt Patch |
| Bayer Healthcare Pharmaceuticals INC. | $68.15 | 2022-2024 | |
| Amgen INC. | $64.48 | 2022-2025 | Evenity, Prolia |
| Astrazeneca Pharmaceuticals LP | $63.70 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Astellas Pharma US INC | $57.06 | 2024-2025 | Veozah |
| Merck Sharp & Dohme LLC | $30.09 | 2019-2023 | Verquvo, Steglatro, Belsomra |
| Xeris Pharmaceuticals, INC. | $29.69 | 2022-2023 | Keveyis |
| Boston Scientific Corporation | $24.03 | 2025 | General - Pain Management |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $22.01 | 2023 | Dexcom G6 Transmitter |
| Mylan Specialty L.P. | $18.44 | 2024 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $15.37 | 2024 | Uptravi, Opsumit |
| Inspire Medical Systems, INC. | $14.98 | 2025 | Inspire |
| Corium, LLC | $12.77 | 2023 | Adlarity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eli Hammer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.